Decreases in serum leptin may be one mechanism by which weight loss improves physical function and symptoms in OA patients.[65] Recent findings suggest that high-fat diet (HFD)-induced obesity can lead to the development of OA, whereas resveratrol may relieve OA pathology by reducing systemic inflammation and/or inhibiting TLR4 signaling in cartilage.[66] Therefore, resveratrol may be a promising treatment for obesity-related OA. Here, LEP is linked to obesity due to melanocortin 4 receptor deficiency.